^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models

Excerpt:
Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2.
DOI:
10.1155/2014/638747